Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0KD4U
|
||||
| Former ID |
DIB009891
|
||||
| Drug Name |
FK-355
|
||||
| Synonyms |
NK1 antagonists, Fujisawa
|
||||
| Indication | Asthma [ICD10:J45] | Terminated | [1] | ||
| Company |
Fujisawa Pharmaceutical Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Substance-P receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014508) | ||||
| REF 2 | FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther. 1992 Jul;262(1):398-402. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.